An interventional study of Iron-biofortified beans and Control beans in Iron-deficiency and Anemia, sponsored by Cornell University. Completed at 1 site in Mexico. Open to participants aged 5 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-19.
Sponsored by Cornell University · Not applicable, Interventional, and Prevention
The objective of this cluster-randomized efficacy feeding trial was to determine the effects of consuming iron-biofortified beans (Fe-Beans) on iron status in children, compared to control beans (Control-Beans). A cluster-randomized trial of biofortified beans (Phaseolus vulgaris L), bred to enhance iron content, was conducted for 6 months.
Iron deficiency is the most common single nutrient deficiency worldwide, with the highest burden in children and women of reproductive age. Global estimates of anemia prevalence in school-aged children range between 25% and 46%, and iron deficiency accounts for a majority of anemia cases. In Mexico, the national nutrition and health survey (2006) reported a prevalence of anemia of 16.6% and iron deficiency of 17.6% (serum ferritin \<12.0 µg/L), posing a considerable health risk for children.
Interventions, including micronutrient supplementation and food fortification, have improved iron status and reduced the prevalence of anemia in some settings. However, iron deficiency remains an urgent public health problem and threat to child health and development. Young children are particularly at high risk due to rapid growth, inadequate dietary intake, and high risk of infection in resource-limited settings. Iron deficiency has been associated with impaired cognitive function in children, and long-term impairments in physical work capacity into adulthood.
One novel approach to reducing micronutrient malnutrition is to enhance the nutrient quality of the diet through biofortification of staple crops that are already locally accepted and consumed. Biofortification has consequently been recognized by the Copenhagen Consensus of 2008 as one of the top five solutions to current global health and nutrition challenges. The success and challenges of biofortification have been documented previously. We recently reviewed the published evidence from the three randomized efficacy trials of different iron-biofortified crops that demonstrated varied benefits in populations, including rice in adult Filipino women, pearl millet in school-aged children in India, and beans in women of reproductive age in Rwanda. Findings demonstrated improvements in serum ferritin concentrations and total body iron concentrations, with additional potential to benefit in individuals who were iron deficient at baseline. Given this limited evidence and with no studies from Latin America, more studies with diverse populations and locally relevant crops are warranted before implementation of a potentially important public health intervention.
In order to target at-risk populations in Latin America, the Centro Internacional de Agricultura Tropical (CIAT) in Colombia bred and biofortified a common black bean variety (Phaseolus vulgaris L), the standard black bean currently consumed widely in Central America and Mexico. In Mexico, beans have been ranked highly among the most consumed foods by school-aged children nationwide, according to Encuesta Nacional de Salud y Nutrición, a nationally representative nutrition survey in 2006. Biofortification has nearly doubled the iron concentration (\~100 versus \~50 mg/kg) of the standard bean variety. We hypothesized that daily consumption of iron-biofortified beans (Fe-Beans) would improve hemoglobin, serum ferritin, and total body iron in 6 months, compared to control beans (Control-Beans). In order to examine this hypothesis, we conducted the first randomized efficacy trial of iron-biofortified beans and iron status in primary school-aged children in a low-income setting in Mexico. Special consideration was applied to assess indicators of iron status with and without anemia and measured inflammatory markers, which can mask iron deficiency, particularly in similar settings where the prevalence of infection is high.
The objective of this cluster-randomized efficacy feeding trial was to determine the effects of consuming iron-biofortified beans (Fe-Beans) on iron status in children, compared to control beans (Control-Beans).
The long-term goal of this study is to determine if iron bio-fortification of beans is an efficacious and potentially effective strategy to improve iron status of at-risk populations in resource-limited settings.
660 studies on the registry are indexed under Anemia, Iron-Deficiency; 106 are open to participants now.
This study's enrollment of 574 is above the median of 100 across 515 interventional studies indexed under Anemia, Iron-Deficiency.
Browse Anemia, Iron-Deficiency studies →Cornell University is the lead sponsor of 103 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Iron-biofortified beans (Phaseolus vulgaris L MIB465)
Other: Iron-biofortified beans
Control beans (Phaseolus vulgaris L Jamapa variety)
Other: Control beans
Iron-biofortified beans (Phaseolus vulgaris L MIB465)
Also known as: Fe-Beans
Control beans (Phaseolus vulgaris L Jamapa variety), identical in color and size
Also known as: Control-Beans
Change in hemoglobin
Hemoglobin (Hb)
Time frame: 6 months
Change in serum ferritin
Serum ferritin (SF)
Time frame: 6 months
Change in sTfR
Soluble transferrin receptor (sTfR)
Time frame: 6 months
Anemia
Hb \<115 g/L for \<12 y; \<120 g/L for \>=12 y
Time frame: 6 months
Iron deficiency (SF)
Serum ferritin \<15.0 µg/L
Time frame: 6 months
Change in TBI
Total body iron (TBI)
Time frame: 6 months
Iron deficiency (TBI)
TBI \<0.0 mg/kg
Time frame: 6 months
Iron deficiency (sTfr)
sTfr \>8.3 μg/mL
Time frame: 6 months
Plan to share: No
Ran from Jan 2010 to primary completion in Jun 2010, 5 months.
Of 127 non-industry interventional studies with no phase under Anemia, Iron-Deficiency, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 27. This study's 5 months is below that.
Counting every sponsor, half of 139 studies reached it within 11 months; a quarter within 4 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.